Leap Therapeutics (NASDAQ:LPTX) Stock Soars To New Highs: But Why?

September 26, 2021

A ray of hope shines for the sufferers of gastroesophageal junction cancer- Leap Therapeutics (NASDAQ:LPTX)  has recently had a breakthrough for a treatment! They have presented initial findings from the first-line cohort of the DisTinGuish study, which is a Phase 2a clinical trial evaluating DKN-01, its anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene Ltd.’s anti-PD-1 antibody, and chemotherapy. No wonder the company’s stock soared by a whopping 105% in…


Leap Therapeutics Inc (NASDAQ:LPTX) Stock Sees Parabolic Rise: Jumps 70% in a Week

September 17, 2021

In the past week, Leap Therapeutics Inc (NASDAQ:LPTX) has garnered considerable attention from investors and the situation remained the same on Thursday as the stock clocked gains of as much as 36%. That took its gains for the past week to as much as 70%. In light of such considerable gains, it might be a good idea for investors to take a closer look at the announcement made by Leap…


Leap Therapeutics Inc (NASDAQ:LPTX) Stock Continues to Attract Buyers: But Why?

September 16, 2021

In the past week, the Leap Therapeutics Inc (NASDAQ:LPTX) stock has emerged as one of the stronger performers and the trend continued on Wednesday. Yesterday, the Leap Therapeutics stock ended the day with gains of 8% and that took its cumulative gains for the past week to as much as 24%. There was no news about the company yesterday but earlier on in the week Leap Therapeutics announced that it…


Leap Therapeutics Inc (LPTX) Stock Sees Value Buying After The News

September 14, 2021

Leap Therapeutics Inc (NASDAQ:LPTX) stock soared 21% on Monday. This rise comes after the company announced that it would present initial results from theDisTinGuish study. The study is a Phase IIa clinical trial for DKN-01, the company’s (DKK1) antibody used with tislelizumab and chemotherapy to treat patients with gastroesophageal junction or gastric cancer. The company has found that DKN-01, when combined with chemotherapy andtislelizumab as the first-line drug for gastroesophageal…